Reforgene's RM001 Achieves Full Transfusion Independence in Pivotal Phase II Beta-Thalassemia Study
Start here
Reforgene Medicine's gene-editing therapy RM001 has achieved transfusion independence in all enrolled subjects in a pivotal Phase II study of transfusion-dependent beta-thalassemia, with follow-up exceeding one year. Across all treated subjects to date, hematopoietic reconstitution and freedom from transfusion dependence were achieved, and the longest follow-up has now reached five years. The results position RM001 as a candidate for a condition currently managed through lifelong transfusion support. Still open are larger-scale confirmation, longer-term safety follow-up beyond the current five-year maximum, and regulatory review that would determine broader patient access.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickReforgene Medicine RM001 Pivotal Phase II Beta-Thalassemia Study Achieves Full Transfusion Independence
Reforgene Medicine announced that RM001, its self-developed gene-editing therapy for transfusion-dependent beta-thalassemia, achieved transfusion independence in all enrolled subjects in a pivotal Phase II study, with follow-up exceeding a year. Across all treated subjects to date, hematopoietic reconstitution and freedom from transfusion dependence were achieved, with the longest follow-up reaching five years.
Coverage and heat for this story
Reports so far 1·Heat now 8·Peak heat 10 (Oct 21 10:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.